Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
266 results found
2022 ∙ Bollaerts, K. Fletcher, M. A. Suaya, J. A. Hanquet, G. Baay, M. Gessner, B. D.
Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials
Newborn Older adults Pneumococcal disease Efficacy/effectiveness
Rating:
Critically low
2022
Recommendations from the Higher Council for Infectious Diseases for vaccination against pneumococcus for populations at risk adults (18 years and over) or aged 65 and over
Recommendation Europe Luxembourg Pneumococcal disease
Download:
2022 ∙ ACIP
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Recommendation Americas United States of America Adults Pneumococcal disease
Download:
2022 ∙ ACIP
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Recommendation Americas United States of America Children Adolescents Pneumococcal disease
Download:
2022 ∙ UNITAG
Advisory on switching PCV products from PCV10 – Synflorix to PCV10 - Pneumosil in Uganda’s routine immunization schedule
Recommendation Africa Uganda Pneumococcal disease
Download:
2022 ∙ Conseil Supérieur de la Santé (CSS)
Vaccination against pneumococcal disease for adults in Belgium
Recommendation Europe Belgium Risk group Pneumococcal disease
Download:
2022 ∙ ACIP
Updates from the Pneumococcal Vaccines Work Group
Background paper Americas United States of America Pneumococcal disease
Download:
2021 ∙ Wang, B. C. Chaiyakunapruk, N. Zhu, S. Babigumira, J. B. Furnback, W. Chitale, R. Gamil, A. Zhao, K. Wasserman, M.
A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019)
Western Pacific Children Newborn Pneumococcal disease Economic aspects
Rating:
Not applicable
2021 ∙ Shao, Y. Stoecker, C.
Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review
Adults Older adults Low and Middle Income Countries Pneumococcal disease Economic aspects
Rating:
Not applicable
2021 ∙ Ishiwada, N.
Current situation and need for prevention of invasive pneumococcal disease and pneumococcal pneumonia in 6- to 64-year-olds in Japan
Western Pacific Japan All age groups Pneumococcal disease Coverage Economic aspects
Rating:
Not applicable
Loading...